COMPANY UPDATES
31
May
2018
Novoheart Becomes Member of International Consortium Advancing Cardiac Safety in Drug Development

Novoheart announced today that it has become a member of the Cardiac Safety Technical Committee of the Health and Environmental Sciences Institute (HESI), an industry-led, international consortium including major pharmaceutical and biotechnology companies that aims to advance innovative approaches for early detection, prediction, and elimination of cardiac risk in drug development.

11
May
2018
Novoheart Holdings Inc. Reports Third Quarter 2018 Financial Results

Novoheart Holdings Inc. reports financial results for the three and nine months ended March 31, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS).

02
May
2018
Novoheart to Debut New, State-of-the-art ‘Human Heart-in-a-Jar 2.0’ Technology at the 2018 International Society for Stem Cell Research (ISSCR) Annual Meeting

Novoheart announced that the next generation of its ‘Human heart-in-a-jar’ technology - which makes up a key component of its comprehensive MyHeartTM Platform - will be unveiled for the first time at the Annual Meeting of the International Society for Stem Cell Research (ISSCR), held in Melbourne, Australia from 20-23 June, 2018. The Annual Meeting is the flagship event of the professional society, where cutting-edge stem cell research will be presented to over 4,000 attendees which include notable scientists, innovators, industry representatives and media.

12
Apr
2018
Novoheart Founder & CEO Dr. Ronald Li honored with 2017 Distinguished Alumnus Award by the University of Waterloo

Novoheart is pleased to announce that Dr. Ronald Li, Founder and CEO of the Company, has been awarded with the 2017 Distinguished Alumnus Award by the University of Waterloo, Canada, from which he graduated with a B.Sc. in 1994. As one of two recipients of the award from the Faculty of Science, Dr. Li is recognized for his two decades of research on human cardiac tissue engineering, and his continuous efforts to translate and commercialize basic findings into tangible applications and community benefits, including the founding of Novoheart in 2014.

Subscribe To Our Newsletter

Fill out the following to subscribe and start receiving updates from us!